“The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers This article explores the key points surrounding this topic, offering insights into recent developments and their implications. The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.
With growing interest and ongoing research, this topic continues to shape our understanding and approach. The findings highlighted in this article contribute to the broader conversation and open doors for future studies and practical applications.”
